Diabetic Polyneuropathy Clinical Trial
— PolyImPActOfficial title:
Polyneuropathy, Impairments and Physical Activity - The PolyImPAct Study
The project aims to investigate the validity, and reliability of outcome measures of muscle strength, functioning (gait, balance, and fine motor skills), physical activity, and patient-reported outcome measures of functioning (gait, balance, and fine motor skills), and daily living among patients with polyneuropathy. Further, the project aims to compare physical activity and patient-reported outcome measures of functioning (gait, balance, and fine motor skills), and daily living among patients with polyneuropathy with physical activity and patient-reported outcome measures of functioning (gait, balance, and fine motor skills) and daily living in healthy adults.
Status | Recruiting |
Enrollment | 520 |
Est. completion date | December 31, 2026 |
Est. primary completion date | December 31, 2026 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 100 Years |
Eligibility | Inclusion Criteria: Inclusion Criteria patients: > 18 years Diagnosed with polyneuropathy (verified by nerve conduction) Inclusion Criteria healthy controls: > 18 years Healthy Exclusion Criteria: Exclusion Criteria patients: Not verified polyneuropathy Exclusion Criteria healthy controls: Diabetes, brain-, nerve-, muscle-, kidney-, or liver disease. Diagnosed with polyneuropathy |
Country | Name | City | State |
---|---|---|---|
Denmark | Copenhagen Neuromuscular Center, Rigshospitalet | Copenhagen |
Lead Sponsor | Collaborator |
---|---|
Rigshospitalet, Denmark |
Denmark,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | 10-meter Walk Test | The patient is asked to 10 meter as fast as possible | At baseline (study entry), after 2-4 weeks, and after 1-2 years | |
Primary | Six Spot Step Test | The patient is instructed to walk 5 meters as fast as possible, while kicking five cylinder blocks out of five circles marked on the floor. | At baseline (study entry), after 2-4 weeks, and after 1-2 years | |
Primary | 6-minute Walk Test | The patient will be asked to walk back and forth along a 25 meter walkway for six minutes. They will be instructed to walk as far as possible for six minutes. | At baseline (study entry), after 2-4 weeks, and after 1-2 years | |
Primary | 30 seconds Chair Stand Test | The patients will be asked to stand up and sit down as many times as possible in 30 secs with their arms across their chest | At baseline (study entry), after 2-4 weeks, and after 1-2 years | |
Primary | Dynamic Gait Index | The patient will be asked to walk while performing different tasks (walking: normally, while changing speed, while turning head (vertical and horizontal), while turning around, while stepping over obstacles, and walking stairs). | At baseline, after 2-4 weeks, and after 1-2 years | |
Primary | Nine Hole Peg Test | Fine motor skills | At baseline (study entry), after 2-4 weeks, and after 1-2 years | |
Primary | Jamar Hand-grip dynamometer (hand-grip-strength) | Best of three values | At baseline (study entry), after 2-4 weeks, and after 1-2 years | |
Primary | Isometric strength measured with hand-held dynamometer | Will be tested bilateral at ankle, knee, wrist and elbow | At baseline (study entry), after 2-4 weeks, and after 1-2 years | |
Primary | Isokinetic muscle strength measured with Biodex System 3 or 4 PRO, Biodex Medical Systems | Will be tested bilateral at ankle and knee | At baseline (study entry), after 2-4 weeks, and after 1-2 years | |
Primary | SENS motion activity sensor (accelerometer) | The SENS motion activity sensor is a wearable accelerometer. It measures physical activity by collecting raw data of accelerations. Data on active time, sedentary time, time spent walking and number of steps taken will be collected.
The sensor will be attached and worn 24/7 (the sensor will be worn the week following baseline tests, and the week after tests at visit three (1-2 years after baseline). |
At baseline (study entry), and after 1-2 years | |
Primary | Inflammatory Neuropathy Cause and Treatment (INCAT) | Interview based disability scale INCAT evaluates disability of the upper and lower limb. The total INCAT score ranges from 0-10 (low scores indicating no disability and higher scores indicating higher level of disability). | At baseline (study entry), after 2-4 weeks, and after 1-2 years | |
Secondary | Rasch-build Overall Disability Scale for Immune-mediated peripheral neuropathies (I-RODS) | I-RODS is a 24-item patient reported outcome measure that measures disability. The raw score ranges from 0-48, with 0 indicating severe disability and higher scores indicating lower levels of disability. | At baseline (study entry), after 2-4 weeks, and after 1-2 years | |
Secondary | Falls Efficacy Scale-International (FES-I) | Assesses limitations related to fear of falling. FES-I is a 16-item patient reported outcome measure that measures fear of falling. The score ranges from 16-64, with higher scores indicating greater fear of falling. | At baseline (study entry), after 2-4 weeks, and after 1-2 years | |
Secondary | Composite Autonomic Symptom Score (COMPAS-31) | Assesses autonomic dysfunction Compass-31 is a patient reported outcome measure that measures autonomic dysfunction. Scores ranges from 0-100, with higher scores indicating more severe symptoms of autonomic dysfunction. | At baseline (study entry), after 2-4 weeks, and after 1-2 years | |
Secondary | Self-reported Leeds Assessment of Neuropathic Symptoms and Signs (S-LANNS) | Assesses neuropathic pain S-LANSS is a patient reported outcome measure for identifying neuropathic pain. | At baseline (study entry), after 2-4 weeks, and after 1-2 years | |
Secondary | Fatigue Severity Scale (FSS) | Assesses fatigue FSS is a 9-item patient reported outcome measure that measures fatigue, and the impact of fatigue on physical activity and daily living. The score ranges from 9-63, with a higher score indicating higher levels of fatigue. | At baseline (study entry), after 2-4 weeks, and after 1-2 years | |
Secondary | PittsburghSleep Quality Index | PittsburghSleep Quality Index is a patient reported outcome measure that assesses sleep quality. The score ranges from 0-21, with higher scores indicating more affected sleep quality | At baseline (study entry), after 2-4 weeks, and after 1-2 years | |
Secondary | Major Depression Inventory (MDI) | MDI is a patient reported outcome measure that measures depressive symptoms. The score ranges from 0-50, with higher scores indicating deeper depression. | At baseline (study entry), after 2-4 weeks, and after 1-2 years | |
Secondary | International Physical Activity Questionaire (IPAQ) | International Physical Activity Questionaire (IPAQ) is a patient reported outcome measure that measures physical activity. | At baseline (study entry), after 2-4 weeks, and after 1-2 years | |
Secondary | Physical Activity Scale (PAS2) | PAS2 is a 7-item patient reported outcome measure that measures physical activity and sedentary behavior. | At baseline (study entry), after 2-4 weeks, and after 1-2 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02423434 -
Evaluation of Corneal Confocal Microscopy for the Identification and Prediction of Neuropathy in Type 1 Diabetes
|
||
Completed |
NCT05542901 -
Comparison of Joint Position Sense in Diabetic and Traumatic Transtibial Amputees
|
N/A | |
Withdrawn |
NCT01536236 -
Spinal Cord Stimulation for Diabetic Polyneuropathy
|
N/A | |
Active, not recruiting |
NCT01175928 -
Pneumatic Medicine: A Transformative Treatment for Diabetic Peripheral Neuropathy
|
Phase 1/Phase 2 | |
Completed |
NCT00993070 -
Efficacy and Safety Study of Topical Capsaicin in Painful Diabetic Neuropathy
|
Phase 2/Phase 3 | |
Completed |
NCT00539175 -
Treatment of Painful Diabetic Neuropathy With Photon Stimulation
|
N/A | |
Completed |
NCT00278980 -
Effect of C-Peptide on Diabetic Peripheral Neuropathy
|
Phase 2 | |
Completed |
NCT04593992 -
HTEMS Treatment of Diabetic Polyneuropathy
|
N/A | |
Completed |
NCT01465620 -
Dietetic and Hygiene Measures in Metabolic Neuropathies: the Neurodiet Study
|
Phase 3 | |
Completed |
NCT01079325 -
Clinical Trial of SB-509 in Subjects With Diabetic Neuropathy
|
Phase 2 | |
Completed |
NCT00406458 -
Clinical Trial of SB-509 in Subjects With Diabetic Neuropathy
|
Phase 2 | |
Recruiting |
NCT06072573 -
Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Diabetic Polyneuropathy
|
Phase 3 | |
Recruiting |
NCT06071975 -
Long Term Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Diabetic Polyneuropathy
|
Phase 3 | |
Recruiting |
NCT05521737 -
Effect of Electroacupuncture on Sensitive Symptoms of Distal Diabetic Peripheral Neuropathy
|
N/A | |
Completed |
NCT01847937 -
Magnetic Resonance Diagnostics of Diabetic Peripheral Neuropathy
|
N/A | |
Completed |
NCT00476931 -
Clinical Trial of SB-509 in Subjects With Diabetic Neuropathy
|
Phase 2 | |
Completed |
NCT00977483 -
Assessment of Efficacy and Safety of Thioctic Acid in the Oral Treatment of Diabetic Polyneuropathy (Stage 1 or 2)
|
Phase 3 | |
Completed |
NCT01006915 -
Surgical Decompression for Diabetic Neuropathy in the Foot
|
N/A | |
Completed |
NCT00501202 -
Study for Safety and Effectiveness of RWJ-333369 (Carsibamate) for the Treatment of Diabetic Peripheral Neuropathy (DPN).
|
Phase 2 | |
Completed |
NCT00307749 -
Safety and Efficacy of MCC-257 in the Treatment of Diabetic Polyneuropathy
|
Phase 2 |